PGGM Investments Reduces Holdings in Hologic, Inc. (NASDAQ:HOLX)

PGGM Investments trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 102,577 shares of the medical equipment provider’s stock after selling 781 shares during the quarter. PGGM Investments’ holdings in Hologic were worth $7,329,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new position in Hologic during the fourth quarter worth $27,000. Venturi Wealth Management LLC purchased a new position in Hologic during the third quarter worth $29,000. NBC Securities Inc. purchased a new position in Hologic during the third quarter worth $33,000. Deseret Mutual Benefit Administrators boosted its stake in Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 227 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HOLX. UBS Group boosted their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Wednesday, April 10th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $87.00.

Hologic Stock Up 0.4 %

Shares of HOLX stock traded up $0.27 on Friday, hitting $75.98. The stock had a trading volume of 919,462 shares, compared to its average volume of 1,442,585. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The business has a 50 day moving average price of $76.03 and a 200 day moving average price of $72.79. The company has a market cap of $17.83 billion, a PE ratio of 36.01, a P/E/G ratio of 2.57 and a beta of 1.00. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.07 earnings per share. Research analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.